BLT2 Inhibitor Compounds Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional compounds exhibiting leukotriene B4 receptor 2 (BLT2) inhibitory activity are metabolically unstable, making them difficult to develop as effective drugs for treating inflammatory diseases.
Innovation Solution
Development of novel compounds such as tert-butyl 4-(4-(3-(N-phenylpentaneamido)prop-1-ynyl)benzoyl)piperazine-1-carboxylate and other structurally related compounds that exhibit BLT2 inhibitory activity, which are more stable and effective in terminating inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional compounds with BLT2 inhibitory activity are used, then anti-inflammatory effect is achieved, but metabolic stability deteriorates
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of BLT2 inhibitor compounds. Specifically, the invention introduces novel molecular structures with different structural parameters (such as specific substituent groups, ring structures, and molecular weight ranges) compared to conventional compounds. These parameter modifications result in compounds that maintain BLT2 inhibitory activity while exhibiting improved metabolic stability, thereby resolving the contradiction between anti-inflammatory efficacy and metabolic stability.
Solution Approach 2:
The patent employs composite materials principle by designing compounds that combine multiple structural features into a single molecular entity. The novel BLT2 inhibitors incorporate composite structural elements including specific core structures with various substituent groups, fused ring systems, and functional groups that work synergistically. This composite approach allows the compounds to achieve both desired pharmacological activity and improved metabolic stability that individual structural features cannot provide alone.
2Reliability
If compounds with multiple double bonds are used to induce inflammation termination, then anti-inflammatory activity is improved, but metabolic stability deteriorates
Solution Approach 1:
The patent resolves this contradiction by carefully controlling the number and position of double bonds within specific ranges. The novel compounds contain a limited number of double bonds (typically 1-3) at strategically positioned locations in the molecular structure, rather than multiple double bonds throughout. This parameter optimization maintains the ability to induce inflammation termination while preventing rapid metabolic degradation that would occur with excessive double bonds.
Solution Approach 2:
The patent applies local quality principle by concentrating functional groups and double bonds in specific localized regions of the molecular structure rather than distributing them throughout. The novel BLT2 inhibitors feature functional groups and unsaturated bonds positioned in specific areas that are less susceptible to metabolic attack, while other regions of the molecule provide structural stability. This localized arrangement preserves anti-inflammatory activity while improving overall metabolic stability.
Data Source
AI summary
The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.